(3-chloro-propyl)-p-tolyl ether | 79096-53-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (3-chloro-propyl)-p-tolyl ether
• 英文别名: (3-Chlor-propyl)-p-tolyl-aether；(γ-Chlor-propyl)-p-tolyl-aether；1-(3-chloropropoxy)-4-methylbenzene；1-Chloro-3-(4-methylphenoxy)propane；3-(4-tolyloxy)-1-chloro propane
• CAS: 79096-53-0
• 化学式: C₁₀H₁₃ClO
• 分子量: 184.666
• InChiKey: YQJAXEQLKNIDSU-UHFFFAOYSA-N

物化性质

• 熔点：
  37-38 °C
• 沸点：
  98-100 °C(Press: 5 Torr)
• 密度：
  1.060±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3-chloro-propyl)-p-tolyl ether 在 乙醇 、 sodium 作用下， 生成 5-(4'-methylphenoxy)pentanoic acid
  参考文献：
  名称：

  Blank, Chemische Berichte, 1892, vol. 25, p. 3044

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(4-methylphenoxy)propan-1-ol 在 吡啶 、 氯化亚砜 作用下， 生成 (3-chloro-propyl)-p-tolyl ether
  参考文献：
  名称：

  据克莱森重排I的知识。（使用14 C进行的实验，第二部分

  摘要：

  1.由放射性氰化钾开始生成其中γ-C原子标记为14 C的对甲酚基烯丙基醚。

  DOI：

  10.1002/hlca.19520350612

文献信息

• N-substituted imidazol derivative
  申请人：Nippon Soda Co., Ltd.

  公开号：US05965743A1

  公开（公告）日：1999-10-12

  The present invention is to provide novel imidazole derivatives effectual as an antihyperlipemic agent and therapeutic and preventive drugs for arteriosclerosis, and to provide methods for manufacturing the said derivatives. More particularly, the present invention is directed to the compounds represented by the following general formula [I]; ##STR1## wherein R.sup.1 is hydrogen or lower alkyl, n is 0 or 1, X is N-r.sup.1 wherein r.sup.1 is hydrogen or lower alkyl, O, S, SO, SO.sub.2, CH.sub.2, CH(CH.sub.3), CONH or C(r.sup.2).dbd.NO wherein r.sup.2 is hydrogen or lower alkyl, m is 0 or an integer of from 1 to 12, and A is methyl or a group represented by the following general formula; ##STR2## wherein Y is N-r.sup.3 wherein r.sup.3 is hydrogen or lower alkyl, N(r.sup.4)SO.sub.2 wherein r.sup.4 is hydrogen or lower alkyl, O, S, SO, SO.sub.2, CH.sub.2, CH(CH.sub.3), CONH or C(r.sup.5).dbd.NO wherein r.sup.5 is hydrogen or lower alkyl, R.sup.2 is a halogen, a lower alkyl, a lower alkoxy, a cycloalkyl or COOr.sup.6 wherein r.sup.6 is hydrogen or a lower alkyl, and l is 0, 1, 2 or 3, however, m denotes an integer of from 6 to 9 when A is methyl, or m denotes 0 or an integer of from 1 to 6 when A is a group represented by the following general formula; ##STR3## and X and Y are each independently CH.sub.2 when m is 0, the pharmaceutically-acceptable salts thereof and methods for manufacturing the said compounds and the pharmaceutically-acceptable salts thereof.

  本发明提供了作为抗高脂血症药物和动脉粥样硬化的治疗和预防药物的新型咪唑衍生物，并提供了制备所述衍生物的方法。更具体地，本发明涉及由以下一般式[I]表示的化合物；其中R.sup.1是氢或较低的烷基，n为0或1，X为N-r.sup.1，其中r.sup.1是氢或较低的烷基，O，S，SO，SO.sub.2，CH.sub.2，CH(CH.sub.3)，CONH或C(r.sup.2).dbd.NO，其中r.sup.2是氢或较低的烷基，m为0或1到12的整数，A为甲基或由以下一般式表示的基团；其中Y为N-r.sup.3，其中r.sup.3是氢或较低的烷基，N(r.sup.4)SO.sub.2，其中r.sup.4是氢或较低的烷基，O，S，SO，SO.sub.2，CH.sub.2，CH(CH.sub.3)，CONH或C(r.sup.5).dbd.NO，其中r.sup.5是氢或较低的烷基，R.sup.2是卤素，较低的烷基，较低的烷氧基，环烷基或COOr.sup.6，其中r.sup.6是氢或较低的烷基，l为0，1，2或3，但当A为甲基时，m表示6到9的整数，或当A为由以下一般式表示的基团时，m表示0或1到6的整数；其中X和Y在m为0时各自独立地为CH.sub.2，其药学上可接受的盐以及制备所述化合物及其药学上可接受的盐的方法。
• [EN] A METHOD OF MANUFACTURING (-)-L-(3-HYDROXYPROPYL)-5-[(2R)-2-({2,2,2-TRIFLUOROETHOXY)- PHENOXYETHYL}AMINO)PROPYL]-2,3-DIHYDRO-LH-INDOLE-7-CARBOXAMIDE<br/>[FR] PROCÉDÉ DE FABRICATION DU COMPOSÉ (-)-L-(3-HYDROXYPROPYL)-5-[(2R)-2-({2,2,2-TRIFLUOROÉTHOXY)-PHÉNOXYÉTHYL}AMINO)PROPYL]-2,3-DIHYDRO-LH-INDOLE-7-CARBOXAMIDE
  申请人：ZENTIVA KS

  公开号：WO2012062229A1

  公开（公告）日：2012-05-18

  A method of manufacturing optically pure or optically enriched silodosin of formula I and of its pharmaceutically acceptable salts, in which a secondary amine of general formula II, wherein Bn denotes a phenylmethyl group, substituted or unsubstituted in the benzene ring, e.g. benzyl or 4-methoxybenzyl, or the benzhydryl or trityl group, (a) is N-alkylated with an alkylating agent of general formula III, wherein X denotes a good leaving group, such as a halogen or an alkane sulfonyloxyl group RS020 or an arene SLilfonyloxyl group ArS020, R means an alkyl group with 1 to 4 carbon atoms and Ar is a substituted or unsubstituted phenyl group; (b) the obtained tertiary amine of general formula IV, wherein Bn is as defined above, is hydrogenolyzed with hydrogen on a metal catalyst; (c) and the resulting nitrile of formula V, wherein Bn is as defined above, is hydrolyzed by treatment with alkaline agents; and optionally, (d) additional O-debenzylation of the amide-ether of general formula VI, wherein Bn is as defined above, with dealkylating agents is carried out; and, if desired, the obtained silodosin is transformed to the respective salts by treatment with pharmaceutically acceptable acids.

  将公式I的光学纯或光学富集硅唑洛新及其药用可接受盐的制备方法，其中一般公式II的二级胺，其中Bn表示苯甲基基团，在苯环中取代或未取代，例如苄基或4-甲氧基苄基，或苯甲基或三苯基基团，（a）与一般公式III的烷基化试剂，其中X表示良好的离去基团，例如卤素或烷基磺酰氧基团RS020或芳基SLilfonyloxyl基团ArS020，R表示具有1至4个碳原子的烷基基团，Ar是取代或未取代的苯基团；（b）所得到的一般公式IV的三级胺，其中Bn如上定义，与金属催化剂上的氢气氢解；（c）并且所得到的一般公式V的腈，其中Bn如上定义，通过碱性试剂处理水解；以及可选地，（d）使用脱烷基试剂对一般公式VI的酰胺-醚，其中Bn如上定义，进行额外的O-脱苄基化反应；如果需要，通过与药用可接受酸处理将所得到的硅唑洛新转化为相应的盐。
• Synthesis and antiallergy activity of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl)piperidines and structurally related compounds
  作者：David A. Walsh、Stephen K. Franzyshen、John M. Yanni

  DOI：10.1021/jm00121a022

  日期：1989.1

  A series of 4-(diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines was synthesized and evaluated for antiallergy activity. Several analogues had potent activity in the passive foot anaphylaxis (PFA) assay, an IgE-mediated model useful in the detection of compounds possessing antiallergic activity. In particular 1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1-piperidinyl] propoxy]-3-methoxyphenyl]ethanone

  合成了一系列的4-（二芳基羟甲基）-1- [3-（芳氧基）丙基]哌啶，并评估了其抗过敏活性。几种类似物在被动足过敏症（PFA）检测中具有有效活性，PFA检测是一种IgE介导的模型，可用于检测具有抗过敏活性的化合物。特别是1- [4- [3- [4- [双（4-氟苯基）羟甲基] -1-哌啶基]丙氧基] -3-甲氧基苯基]乙酮（1，AHR-5333）比奥沙米特和特非那定在这种测定。
• Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a
  申请人：A. H. Robins Company, Incorporated

  公开号：US04950674A1

  公开（公告）日：1990-08-21

  A method of inhibiting Type 1 allergic responses in a living animal body with substituted heterocyclic amines is disclosed wherein the active agents are expressed generally by the formula which includes certain known and certain known compounds: ##STR1## wherein P is zero, one or two; m is one to six inclusive; A is selected from hydrogen, hydroxy or cyano; d is zero or one; Q is --CH--, CH.sub.2 -- or ##STR2## n is zero or one and when Q is --CH-- and n is one, a double bond is formed with one of the adjacent carbons but not both at the same time, and when n and d are zero at the same time, a double bond is formed between the .alpha. carbon and a carbon of the central heterocyclic amine ring; Ar, D and R are selected from phenyl, substituted phenyl, pyridinyl, thienyl, furanyl or naphthyl and in addition, R may have the values benzyl, substituted benzyl, cycloalkyl or loweralkyl and D may additionally have the values: 2H-1-benzopyran-2-one,4-oxo-4H-1-benzopyran-2-carboxylic acid loweralkyl ester, 2,3-dihydro-4H-1-benzopyran-4-one, 1,4-benzodioxanloweralkyl-2-yl or 1,1'-biphenyl-4-yl and the pharmaceutically acceptable salts thereof.

  揭示了一种利用取代杂环胺抑制活体动物体内的1型过敏反应的方法，其中活性剂通常由以下公式表示：其中P为零、一或二；m为一到六（包括六）；A选自氢、羟基或氰基；d为零或一；Q为--CH--、CH.sub.2--或n为零或一，当Q为--CH--且n为一时，与相邻碳之一形成双键，但不同时与两个相邻碳形成双键；当n和d同时为零时，在中心杂环胺环的α碳和一个碳之间形成双键；Ar、D和R选自苯基、取代苯基、吡啶基、噻吩基、呋喃基或萘基，此外，R可能具有苄基、取代苄基、环烷基或较低烷基的值，D还可能具有以下值：2H-1-苯并吡喃-2-酮、4-氧代-4H-1-苯并吡喃-2-羧酸较低烷基酯、2,3-二氢-4H-1-苯并吡喃-4-酮、1,4-苯并二氧杂环较低烷基-2-基或1,1'-联苯基-4-基，以及其药学上可接受的盐。
• Selectivity in Alkylation of Phenols with 1-Bromo-3-chloropropane Using Phase-Transfer Catalysis
  作者：E. Reinholz、A. Becker、B. Hagenbruch、S. Schäfer、A. Schmitt

  DOI：10.1055/s-1990-27096

  日期：——

  The use of various phase-transfer catalysts in the alkylation of phenol and substituted phenols with 1-bromo-3-chloropropane was investigated. When a quarternary ammonium salt of the general formula R′4N+ X-, where R′ = alkyl with a minimum chain length of 4 was used, a mixture of 1-aryloxy-3-chloropropane and 1-aryloxy-3-bromopropane resulted. The effect of counterion, added potassium bromide, and catalysts other than quarternary ammonium salts were assessed for the halopropylation of 2,5-dimethylphenol.

  研究了在1-溴-3-氯丙烷与酚及其取代酚的烷基化反应中使用各种相转移催化剂的情况。当使用一般式为R′4N+ X-的季铵盐时，其中R′为最小链长为4的烷基，结果得到1-芳氧-3-氯丙烷和1-芳氧-3-溴丙烷的混合物。评估了对2,5-二甲基酚进行卤丙基化反应时，反离子、添加的溴化钾以及其他催化剂（除了季铵盐）的影响。